Cramps in the legs

Active substance:


Pharmacological group

Nosological classification (ICD-10)

3D images

Description of the dosage form

Round biconvex tablets, coated pink.

pharmachologic effect


The drug has a phlebotonizing effect (reduces vein distensibility, increases vein tone – dose-dependent effect; reduces venous congestion), improves lymphatic drainage (increases tone and frequency of lymphatic capillary contractions, increases their functional density, reduces lymphatic pressure), improves microcirculation (increases capillary resistance – dose-dependent effect; reduces their permeability), reduces the adhesion of leukocytes to the venous wall and their migration into paravenous tissues, improves the diffusion of oxygen a and perfusion in the skin tissue, possesses anti-inflammatory action. Strengthens the vasoconstrictor action of adrenaline, norepinephrine, blocks the production of free radicals, the synthesis of PG and thromboxane.


Quickly absorbed from the gastrointestinal tract, detected in the plasma after 2 h after administration. Cmax in plasma is reached 5 h after administration. It is evenly distributed and accumulated in all layers of the wall of the hollow veins and saphenous veins of the lower extremities, to a lesser extent in the kidneys, liver, lungs and other tissues. Selective accumulation of diosmin and / or its metabolites in venous vessels reaches a maximum after 9 hours after administration and lasts for 96 hours. It is eliminated by the kidneys – 79%, by the intestine – 11%, with bile – 2.4%.

Indications drug Flebodia 600

In the complex therapy:

elimination of symptoms of lymphovenous insufficiency of the lower extremities: feeling of heaviness or fatigue in the legs, pain;

additional treatment in violation of microcirculation;

acute hemorrhoids (symptomatic therapy).


hypersensitivity to the drug;

Cramps in the legs

breastfeeding period;

pregnancy (I term – limited experience);

children’s age (under 18 years).

Use during pregnancy and lactation

Until now, in clinical practice, there have been no reports of any side effects when using the drug in pregnant women.

Application during pregnancy in the II and III trimesters is possible only on prescription of the doctor in cases where the expected benefit to the mother outweighs the potential risk to the fetus.

In experimental studies, no teratogenic effects on the fetus were identified. During breastfeeding is not recommended taking the drug,

Side effects

In rare cases – hypersensitivity to the components of the drug (requiring a break in treatment).

On the part of the digestive tract: dyspeptic disorders (heartburn, nausea, abdominal pain).

CNS: headache.

If any of the side effects indicated in the description are exacerbated, or the patient has noticed any other side effects that are not listed in the description, you should inform your doctor.


Clinically significant effects of interaction with other drugs are not described.

Dosage and administration

Inside Before using the drug should consult a doctor.

With varicose veins of the lower extremities and chronic lymphatic insufficiency (edema, pain, convulsions) – 1 tabl. per day in the morning on an empty stomach. The duration of therapy is usually 2 months.

With exacerbation of hemorrhoids – 2-3 tablets. per day with meals for 7 days. If you miss one or more doses of the drug, it is necessary to continue the use of the drug in the usual mode and in the usual dose.


Symptoms of overdose are not described.

special instructions

Treatment of an acute attack of hemorrhoids is carried out in combination with other drugs, in the absence of a rapid clinical effect, it is necessary to conduct an additional examination and adjust the therapy being conducted.

Impact on the ability to drive. There is no evidence of a negative effect of the drug on the ability to drive vehicles and other mechanisms.

Release form

Tablets, film coated. At 15 tab. in PVC / aluminum blister. 1 or 2 bl. in a carton box.


Innotera Shuzi. Rue Rene Shantero, L’Isle Ver, 41150, Chiusi-sur-Cis, France.

Registration certificate holder: Innotech Internationale Laboratory. 22, Avenue Aristide Briand, 94110 Arkay, France.

Russian representative office of JSC Innotech Internacional Laboratory (France): 127051, Moscow, ul. Petrovka, 20/1.

Tel: (495) 775-41-12; fax: (495) 287-87-68.

Pharmacy sales terms

Storage conditions of the drug Flebodia 600

Keep out of the reach of children.

Expiration date of the drug Phlebodia 600

Do not use after the expiration date printed on the package.

Like this post? Please share to your friends:
Leave a Reply